ANIP 52.11 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 10:19 AM

ANIP 52.11 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high of 53.20 Closing the day 09:45 at 52.11 -0.59 -1.12% With a day low of 51.91 and a total volume of 25,067.

ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/

ANIP ANI Pharmaceuticals Inc Recent Headline News

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 44 mins ago
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 52.36 (-0.34), ICPT: 161.65 (-1.31), AMAG: 34.71 (-0.22), AFFX: 9.79 (+0.01)

Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 51 mins ago
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 52.36 (-0.34)

ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 52.36 (-0.34), SCMP: 11.50 (+1.08)

Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 52.36 (-0.34)

Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 321.32 (+0.30), ANIP: 52.36 (-0.34), CLDX: 15.12 (+0.31), AMAG: 34.71 (-0.22)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.01 (-0.08), ANIP: 52.36 (-0.34), ACGL: 57.61 (+0.19), ACCO: 8.92 (+0.06), FLWS: 9.18 (+0.15)

ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 52.36 (-0.34)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 24.15 (-0.17), HBNK: 20.20 (unch), ASMI: 41.41 (+0.41), RRGB: 69.78 (+0.02), SAPE: 24.73 (+0.10), PLUG: 4.27 (+0.03), ANIP: 52.36 (-0.34), ODP: 6.83 (-0.01), MTEX: 23.15 (+0.37), JAXB: 11.75 (-0.15), ALQA: 5.20 (+0.10), YRCW: 24.68 (-0.02)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 6.45 (-0.14), NEO: 4.90 (-0.04), AU: 8.82 (-0.18), FNHC: 26.15 (+0.37), AMS: 2.81 (+0.30), NYMX: 0.53 (-0.05), AMDA: 1.27 (+0.02), CVD: 100.74 (+0.01), GBIM: 6.48 (+0.03), RCAP: 9.79 (-1.80), KBIO: 2.09 (-0.02), COOL: 0.96 (+0.04), SAPE: 24.73 (+0.10), XTLB: 2.40 (-0.18), GERN: 2.39 (+0.02), ANIP: 52.36 (-0.34), BBLU: 1.38 (+0.07), NXTD: 2.47 (+0.01), AP: 18.95 (+0.26), ALQA: 5.20 (+0.10)

ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST

ANIP: 52.36 (-0.34)

ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 52.36 (-0.34)

ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST

ANIP: 52.36 (-0.34)

ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"

(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 52.36 (-0.34)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.94 (+0.07), SYY: 38.98 (+0.04), L: 43.11 (-0.14), EEP: 36.86 (+0.27), SNH: 22.33 (+0.01), INN: 11.57 (-0.04), ITG: 19.62 (+0.03), NSP: 33.60 (-0.22), S: 5.04 (+0.04), ALE: 50.84 (-0.41), GVA: 37.51 (-0.08), MCY: 55.28 (+0.14), ARNA: 4.83 (+0.13), CHD: 74.56 (+0.22), ARE: 83.09 (+0.34), USAK: 18.45 (-0.03), BWP: 16.96 (-0.10), KRG: 26.87 (+0.07), CYOU: 22.52 (-0.28), MNKD: 6.26 (+0.18), HNT: 49.92 (+0.47), AMH: 17.28 (+0.07), ARCB: 43.11 (-0.27), ANIP: 52.36 (-0.34), AMG: 198.98 (-1.25), HAE: 37.15 (+0.10), SOHU: 51.30 (+0.04), CNA: 39.23 (-0.30)

ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 106.23 (-0.10), MACK: 8.45 (-0.10), ANIP: 52.36 (-0.34), ILMN: 190.94 (+4.02)

ANI Pharma reports November 3
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:35AM CDT

ANIP: 52.36 (-0.34)

5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 52.36 (-0.34), KTOS: 5.37 (+0.03), BLOX: 16.93 (+0.11), CSLT: 12.05 (-0.10), FPRX: 14.32 (-0.22)

ANI Pharmaceuticals Schedules Conference Call for Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 7:30AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2014 financial results on Monday, November 3, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 52.36 (-0.34)

3 Money-Making Biotech Stocks That Could Go Higher
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 24, 7:34AM CDT
Biotechnology investors often have to make bets based more on promise than profit. That's because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of...
INSY: 38.90 (-0.75), ANIP: 52.36 (-0.34), AMGN: 161.47 (-0.46), NPSP: 29.50 (+0.33), TEVA: 58.21 (-0.23)

ANI Pharmaceuticals Inc. (ANIP) Stock Research Links

ANIP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...